Prescient Therapeutics Initiates First Clinical Site for PTX-100 Phase 2a Study

Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.

Prescient Therapeutics Limited has announced the initiation of its first clinical site for the Phase 2a study of PTX-100, a potential treatment for Cutaneous T-Cell Lymphoma (CTCL). This milestone marks the beginning of a multi-site study across Australia, the USA, and Europe, evaluating the efficacy and safety of PTX-100 in approximately 40 patients. The study’s progress is significant for the company’s operations as it advances its first-in-class therapeutic candidate, potentially impacting its positioning in the oncology market and offering new hope for CTCL patients.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment, including targeted and cellular therapies. Their product PTX-100 is a first-in-class compound targeting the cancer growth enzyme GGT-1, and they are also developing cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR.

YTD Price Performance: -12.00%

Average Trading Volume: 483,518

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$37.85M

Learn more about PTX stock on TipRanks’ Stock Analysis page.